Siegfried Holding AG, together with its subsidiaries, is a contract development and manufacturing organization for active pharmaceutical ingredients (APIs) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis of custom APIs, as well as a portfolio of non-exclusive APIs and pharma-grade substances focused on anesthetics, pain and addiction treatment, central nervous and respiratory diseases, and caffeine for human health and nutrition. The company also provides drug products such as sterile fill-and-finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics including sterile ointments, gels, suspensions, and solutions; inhalation products including capsules in medical devices; oral solid dosage forms such as tablets and capsules; and viral vectors including AAV and lentiviruses for gene therapy. In addition, it offers technologies and services in chemistry, analytics, formulation, bridging, containment, and cell and gene therapies. Founded in 1873, Siegfried Holding AG is headquartered in Zofingen, Switzerland.